O
TAK icon

OrbiMed’s Takeda Pharmaceutical TAK Stock Holding History

OrbiMed’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-750,000
Closed -$12.9M – 146
2019
Q3 		$12.9M Hold
750,000
– – 0.24% 75
2019
Q2 		$13.3M Hold
750,000
– – 0.21% 84
2019
Q1 		$15.3M Buy
+750,000
New +$15.1M 0.24% 84

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

OrbiMed's TAK Position: Q4 2019 in Review

OrbiMed sold out of Takeda Pharmaceutical (TAK) in Q4 2019, closing a stake of 750,000 shares — an estimated $12.9M sold.

OrbiMed first reported a position in TAK in Q1 2019 and held it in 3 quarters. The position peaked at $15.3M in Q1 2019. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

  • OrbiMed reported no remaining Takeda Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • OrbiMed sold 750,000 Takeda Pharmaceutical shares in Q4 2019, an estimated $12.9M.
  • OrbiMed first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 3 quarters.
  • OrbiMed's Takeda Pharmaceutical position peaked at $15.3M in Q1 2019.
  • 339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.